FREEDOM OF INFORMATION ACT 2000

THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST

Date Request Received: 25th September 2020 FOI Ref: 11469

Requested Information Could you please answer the following four questions for patients treated by your trust?

1) How many patients are currently (past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+ ?

2) For patients currently (past 3 months) under treatment for melanoma

a) How many patients are Stage IIIa? b) How many patients are Stage III resectable? c) How many Stage III patients received a complete resection in the past 3 months?

3) In the past 3 months, how many melanoma patients were treated with the following:

Bevacizumab Cobimetinib Dabrafenib Dabrafenib AND Trametinib Dacarbazine Encorafenib AND Binimetinib Ipilimumab Ipilimumab AND Nivolumab Nivolumab Pembrolizumab Trametinib Vemurafenib Vemurafenib AND Cobimetinib Other active systemic anti-cancer therapy Palliative care only

4) In the past 3 months how many patients were treated with the following for breast cancer?

Abemaciclib + Anastrozole/Exemestane/Letrozole Abemaciclib + Fulvestrant Alpelisib + Fulvestrant Atezolizumab Bevacizumab Eribulin Everolimus + Exemestane Fulvestrant as a single agent Gemcitabine + Paclitaxel Lapatinib Neratinib Olaparib Palbociclib + Anastrozole/Exemestane/Letrozole

Jemma Dunstan, Information Governance Team V1 Review Date: 2030 Page 1 of 3

Palbociclib + Fulvestrant Pertuzumab + Trastuzumab + Docetaxel Ribociclib + Anastrozole/Exemestane/Letrozole Ribociclib + Fulvestrant Talazoparib Transtuzumab + Paclitaxel Transtuzumab as a single agent Trastuzumab emtansine Any other active systemic anti-cancer therapy

Response

1) During the past 3 months 56 patients have undergone treatment for melanoma across the Royal Cornwall Hospitals Trust. The Trust is unable to provide the number of patients that are BRAF+ as this information is documented within the individual patient record and not recorded on our electronic systems, therefore it would require a manual review of each set of notes; however, there is no way to narrow the scope of the manual search that would be required to determine what is being asked. I have therefore estimated that it would exceed the appropriate limit1 to proceed with your request

2) The Royal Cornwall Hospitals Trust is unable to provide the number of Stage IIIa, Stage III Resectable or Stage III patients received a complete resection in the past 3 months as this information is documented within the individual patient record and not recorded on our electronic systems, therefore it would require a manual review of each set of notes; however, there is no way to narrow the scope of the manual search that would be required to determine what is being asked. I have therefore estimated that it would exceed the appropriate limit1 to proceed with your request

3) The table below details the number of melanoma patients treated across the Royal Cornwall Hospitals Trust with the following:

Drug Number of patient Treated Bevacizumab 0 Cobimetinib 0 Dabrafenib 0 Dabrafenib AND Trametinib 2 Dacarbazine 1 Encorafenib AND Binimetinib 10 Ipilimumab 1 Ipilimumab AND Nivolumab 2 Nivolumab 7 Pembrolizumab 33 Trametinib 0 Vemurafenib 0 Vemurafenib AND Cobimetinib 0 Other active systemic anti-cancer 0 therapy Palliative care only This information is documented within the individual patient record and not Jemma Dunstan, Information Governance Team V1 Review Date: 2030 Page 2 of 3

recorded on our electronic systems, therefore it would require a manual review of each set of notes; however, there is no way to narrow the scope of the manual search that would be required to determine what is being asked. I have therefore estimated that it would exceed the appropriate limit1 to proceed with your request

4) The table below details the number of patients that were treated with the following for breast cancer during the past 3 months

Drug Number of patient Treated Abemaciclib + 0 Anastrozole/Exemestane/Letrozole Abemaciclib + Fulvestrant 3 Alpelisib + Fulvestrant 0 Atezolizumab 0 Bevacizumab 0 Eribulin 3 Everolimus + Exemestane 1 Fulvestrant as a single agent 32 Gemcitabine + Paclitaxel 0 Lapatinib 0 Neratinib 0 Olaparib 0 Palbociclib + 37 Anastrozole/Exemestane/Letrozole Palbociclib + Fulvestrant 15 Pertuzumab + Trastuzumab + 4 Docetaxel Ribociclib + 21 Anastrozole/Exemestane/Letrozole Ribociclib + Fulvestrant 7 Talazoparib 0 Transtuzumab + Paclitaxel 6 Transtuzumab as a single agent 27 Trastuzumab emtansine 4 Any other active systemic anti-cancer 173 therapy

Attachment(s) None

Date Response Sent: October 2020 1The appropriate limit is specified in regulations and for RCHT this is set at £450. This represents the estimated cost of 1 person spending 2½ working days in determining whether RCHT hold the information, locating, retrieving and extracting the information. Consequently RCHT is not obliged under Section 12 of the Freedom of Information Act 2000 to respond to this part of your request. Jemma Dunstan, Information Governance Team V1 Review Date: 2030 Page 3 of 3